Skip to main content
Menu
US
US

Obesity, Diabetes and Metabolic Disease Reagents

Obesity and metabolic disorders: from socio-economic impact to next-generation therapeutics

Among metabolic disorders, obesity has become a new pandemic affecting 890 million people according to WHO reports1 and is on the rise in developed countries where it brings massive socio-economic challenges. Obesity is strongly associated with cardiovascular disorders, cancers, respiratory troubles, etc; and typically, occurs concurrently to other metabolic disorders like Type 2 Diabetes, MASH (Metabolic dysfunction-associated steatohepatitis), and MALFD (Metabolic dysfunction–associated steatotic liver disease) also known as human fatty liver disease. As such, there are important public-health and economic interests in addressing it with therapeutics.

In recent years, Novo Nordisk® and Eli Lilly have disrupted this environment with their successful FDA-approved weight loss medications Semaglutide (GLP-1R agonist) and Tirzepatide (GLP-1R and GIPR dual agonist), which were initially approved for Type 2 Diabetes only.

In the wake of these successes, it is estimated over 60 organizations initiated investigations into 100+ molecules, which set the perspective for the next generation of weight-loss drugs on the 2027 horizon. The next generation of drug candidates are building upon Semaglutide and Tirzepatide by either moving away from injectable peptides in favor of oral small molecules and nanobodies, or by designing peptides exhibiting triple agonism for GLP-1R, GIPR, and GCCR (such as Eli Lilly’s Retatrutide/LY3437943, already undergoing clinical trials).

While Semaglutide, Tirzepatide, and Retatrutide are a benchmark for ongoing and future drug candidates and investigations, the GPCRs they target are far from being the only set of receptors of interest in the race to weight-loss medications. Molecules such as Dapiglutide (GLP-1R and GLP-2R dual agonist), Setmelanotide (MC4R agonist), Cagrilintide (AMYRs agonist), and Monlunabant (CB1R inverse agonist) already demonstrate the potential other receptors hold for weight loss drug treatment.

Revvity has accompanied these developments from the start with a 360° portfolio of assays and reagents dedicated to GPCR and cell signaling pathways related to metabolism, including Gi, Gs, Gq second messengers to Beta-Arrestin recruitment, downstream signaling protein detection, and time-resolved binding assays for pharmacodynamic studies of ligand/receptor interactions. Our assays and reagents fit at multiple stages of the drug discovery process, including screening and are largely referenced in the dedicated literature.2-8 On top of our GPCR reagents, we also carry an extensive portfolio of diabetes research reagents and MASH & MAFLD research reagents, to investigate the mechanism at play in these critical metabolic disorders that often accompany obesity.
 


For research use only. Not for use in diagnostic procedures.

Obesity, Diabetes and Metabolic Disease Reagents
b-arrestinAP2GbGgGai/sAdenylate cyclasePIP2Ca2+ flux increaseDownstream signalingIP3IP2IP1c-RAFMEK1/2ERK1/2CREBBADcAMPATPGbGgGaPLCPKAClathrinReceptor internalizationG-alternative signalingPKCTag-lite receptor binding assayMAP KinasePathwayMAP KinasePathwayPhospho KitsIP-One KitsArrestin KitscAMP KitsKey receptors for obesityGs-coupledGLP-1RGLP-2RGIPRGCGRMC4RAMYRsGi-coupledCB1RSecondary Gq-couplingMC4RGIPRGLP1R

Diabetes: assays tailored for insulin and glucagon studies

Revvity focuses on providing assays that help cover your needs and make research more straightforward. With our kits, everything stays in focus:

  • Ultra-sensitive and high-range insulin assays covering a dynamic range from 0.004 ng/mL to 150 ng/mL
  • Diverse and relevant models, such as human, rat, mouse, and pig, for insulin and glucagon assays
diabetes-lookbook-insulin-ultra-sensitive

Metabolic disorders

Revvity enables you to explore the world of metabolic disorders with reliable and easy-to-use immunoassays based on HTRF™ and Alpha™ technologies. We are dedicated to helping scientists discover new therapies and have developed many assays to reach that exact objective!

Whether you work on fibrosis, psoriasis, obesity, or any other disorder, it is very likely you will find what you need in our assay line, ranging from target identification and screening to pre-clinical sample testing. See our catalog for complete descriptions.

bg-element-listing-page bg-element-listing-page-mobile
Products & Services
Resource Library
Filters
Expand All|Collapse All
Product Type
Application
Brand
Cellular or Signaling Pathway
Color
Detection Modality
Fluorophore
Host Species
Plate Format
Product Group
Receptor
Sterility
Surface Treatment
Target
Target Class
Target Species
Therapeutic Area
Validation
Well Shape
Sort by: Recommended
Recommended
Product Name A-Z
Product Name Z-A
Price - low to high
Price - high to low
1 - 25 of 1119 Products and Services
Shipping box for Revvity reagent kits

The Human FLT3 kit is designed to monitor the expression level of cellular FLT3. This kit can be used as a normalization assay with our Phospho-FLT3 Tyr 589/591 and Phospho-FLT3 Tyr 842 kits to enable optimal investigation of the FLT3 pathway.

Part Number: 64FLT3TPEG, 64FLT3TPEH
List price:
USD 2,271.53 - 13,214.42
Shipping box for Revvity reagent kits

This HTRF kit enables the cell-based quantitative detection of human total VAV1 (Vav proto-oncogene 1), as a readout of the signaling activity of adaptive immunity receptors, specifically T-cell receptor (TCR) and B-cell receptor (BCR).

Part Number: 64VAV1TPEG, 64VAV1TPEH
List price:
USD 2,271.53 - 13,214.42
Shipping box for Revvity reagent kits

This HTRF kit enables the cell-based quantitative detection of total PINK1 as a readout of the Mitophagy pathway.

Part Number: 64PINKTPEG, 64PINKTPEH
List price:
USD 2,271.53 - 13,214.42
Photo ATM Phospho-S1981 Kit

This HTRF kit enables the cell-based quantitative detection of ATM phosphorylation at Ser1981, which is activated upon DNA damage. This kit enables optimal investigation of the ATM/CHK2 pathway, including selective inhibitors.

Part Number: 64ATMS1PEG, 64ATMS1PEH
List price:
USD 2,271.53 - 13,214.42
Photo Aurora A Phospho-T288 Kit

This HTRF kit enables the cell-based quantitative detection of phosphorylated human Aurora A at Thr288.

Part Number: 64AURAT2PEG, 64AURAT2PEH
List price:
USD 2,271.53 - 13,214.42
Shipping box for Revvity reagent kits

The Total Cyclin E1 kit is designed to monitor the expression level of cellular Cyclin E1, an oncogene overexpressed in many human cancers.

Part Number: 64CYCE1TPEG, 64CYCE1TPEH
List price:
USD 2,271.53 - 13,214.42
Photo CCL22 Kit

The HTRF Human CCL22 kit is designed for the quantification of human CCL22 release in cell supernatant.

Part Number: 62HCCL22PEG, 62HCCL22PEH
List price:
USD 1,149.33 - 10,722.18
Shipping box for Revvity reagent kits

This HTRF enables the cell-based quantitative detection of Alpha-Synuclein when phosphorylated at Ser129 and aggregated.

Part Number: 64SYN29AGPEG, 64SYN29AGPEH
List price:
USD 2,271.53 - 13,214.42
Photo ATG14 Total Kit

This HTRF kit enables the cell-based quantitative detection of ATG14 as a readout of the autophagy pathway, and can be combined with our Phospho-ATG14 Ser 29 kit.

Part Number: 64ATG14TPEG, 64ATG14TPEH
List price:
USD 2,271.53 - 13,214.42
Shipping box for Revvity reagent kits

The Progranulin HTRF kit is designed for the accurate quantitative measurement of Progranulin produced by cells.

Part Number: 62PROPEG, 62PROPEH
List price:
USD 1,305.63 - 13,556.42
HTRF Human and Mouse Phospho-Cofilin Ser3 Detection Kit

This HTRF kit enables the cell-based quantitative detection of Cofilin phosphorylation at Ser3.

Part Number: 64COFS3PEG, 64COFS3PEH
List price:
USD 2,271.53 - 13,214.42
Shipping box for Revvity reagent kits

This HTRF kit enables the cell-based quantitative detection of phosphorylated CDK1 (Cyclin-Dependent Kinase 1) at Tyr 15, which is an inhibitory phospho-site essential for maintaining genome integrity and preventing DNA damage during the G2-M phase transition.

Part Number: 64CDK1Y5PEG, 64CDK1Y5PEH
List price:
USD 2,237.17 - 13,014.58
Picture of HTRF AAV9 kit

The AAV9 Capsid kit is designed for the quantitative measurement of Adeno-associated virus serotype 9 (AAV9) particles in both cell lysates and cell supernatants.

Part Number: 64AAV9PEG, 64AAV9PEH
List price:
USD 2,295.28 - 23,732.80
Shipping box for Revvity reagent kits

The AAV3B Capsid kit is designed for the quantitative measurement of Adeno-associated virus serotype 3B (AAV3B) particles in both cell lysates and cell supernatants.

Part Number: 64AAV3PEG, 64AAV3PEH
List price:
USD 1,986.30 - 23,732.80
Shipping box for Revvity reagent kits

The HTRF Human ADAR1 Detection Kit is designed to monitor the expression level of cellular ADAR1.

Part Number: 64ADAR1TPEG, 64ADAR1TPEH
List price:
USD 2,271.53 - 13,214.42
Picture of HTRF RAB10 kit

The HTRF total RAB10 kit is designed to monitor the expression level of cellular RAB10, a RAB GTPase that regulates intracellular membrane trafficking. This kit can be used as a normalization assay with our Phospho-RAB10 Thr73 kit.

Part Number: 64RAB10TPEG, 64RAB10TPEH
List price:
USD 2,271.53 - 13,214.42
Photo ATG14 Phospho-S29 Kit

This HTRF kit enables the cell-based quantitative detection of ATG14 phosphorylation at Ser29 as a readout of the autophagy pathway.

Part Number: 64ATG14S9PEG, 64ATG14S9PEH
List price:
USD 2,271.53 - 13,214.42
Shipping box for Revvity reagent kits

The HTRF Human Phospho-MET Tyr1234/1235 detection kit is designed to monitor the expression level of cellular MET phosphorylated at Tyrosine 1234/1235.

Part Number: 64METY34PEG, 64METY34PEH
List price:
USD 2,271.53 - 13,214.42
Shipping box for Revvity reagent kits

The HTRF Total MET detection kit is designed to monitor the expression level of cellular MET.

Part Number: 64METTPEG, 64METTPEH
List price:
USD 2,271.53 - 13,214.42
Shipping box for Revvity reagent kits

The Total RBM39 kit is designed to quantify the expression level of RBM39 in cells

Part Number: 64RBM39TPEG, 64RBM39TPEH
List price:
USD 2,271.53 - 13,214.42
Shipping box for Revvity reagent kits

Phospho-IKK-alpha (Ser176/180) assay enables the cell-based detection of Ser176/180 phosphorylation of activated IKK-alpha directly in whole cells.

Part Number: 64KKAS6PEG, 64KKAS6PEH
List price:
USD 2,271.53 - 13,214.42
Shipping box for Revvity reagent kits

This HTRF kit enables the cell-based quantitative detection of mouse phosphorylated STING as a readout of the activation of the cGAS-STING pathway.

Part Number: 64MSTGPEG, 64MSTGPEH
List price:
USD 2,271.53 - 13,214.42
Shipping box for Revvity reagent kits

The HTRF Human Total cGAS detection kit is designed to monitor the expression level of cellular cGAS.

Part Number: 64CGASTPEG, 64CGASTPEH
List price:
USD 2,271.53 - 13,214.42
Shipping box for Revvity reagent kits

The Total EGFR EX19DEL kit is designed to quantify the expression level of EGFR mutant DEL19 in cells

Part Number: 64EGFRD19PEG
List price:
USD 2,271.53
Shipping box for Revvity reagent kits

The Total H2AX kit is designed to monitor the expression level of cellular human H2AX, and can be used as a normalization assay for the Phospho-H2AX (Ser139) Detection kit.

Part Number: 64H2AXTPEG, 64H2AXTPEH
List price:
USD 2,271.53 - 13,214.42
Filters
Expand All|Collapse All
Resource Type
Sort by: Resource Name A-Z
Resource Name A-Z
Resource Name Z-A
1 - 25 of 136 Resources
Application Note
Application Note
A guideline for HTRF cell-based phospho-protein data normalization

Get the best out of your phosphorylation assays Combining phospho and total protein assays enables better analysis. This Application Note provides valuable guidelines for efficiently analyzing and interpreting results from such assay combinations. Check out all the tips and examples in features! Features Introduction to phospho and total protein assay relevance Tips for handling and interpreting data Examples from actual experiments

Technical Note
Technical Note
A simple method for preparing GPCR membrane model extracts from stable cell lines for use with the HTRF GTP Gi binding assay

G-protein coupled receptors (GPCRs) are crucial transmembrane proteins involved in cellular signal transduction. This technical note outlines a method for preparing GPCR membrane model extracts from stable cell lines, specifically for use with the HTRF GTP Gi binding assay. Get this technical note and discover: Key Highlights such as the Importance of GPCRs and the advantages of using HTRF GTP Gi Binding Assay Detailed Method with Cell Culture Preparation, Cell Lysis, Membrane Preparation and Assay Optimization For research use only. Not for use in diagnostic procedures.

Infographic
Infographic
Addressing the interactome with protein-protein interaction assays

Protein-protein interactions: cover them all with one approach This brochure illustrates the possibilities and versatility of protein-protein interaction studies. It features six relevant examples of various interaction types taken from literature to show you how studies can be handled with the time-resolved fret-based HTRF approach, including virus blockade, receptor/ligand binding, protease activity, and more. Features: Introduction to the stakes of protein-protein interaction research Illustration of 6 published interaction studies involving biologics or small molecules For research use only. Not for use in diagnostic procedures.

Whitepaper
Whitepaper
Adeno-Associated Virus (AAV) Vectors Manufacturing

What Are the Challenges and Solutions? All across the globe, AAVs are getting the attention of scientists and companies working in gene therapy, as they provide the right combination of characteristics that make them one of the most promising vector today. In 2021 only, the global gene therapy market was 4.1 billion USD, and AAV vector therapies made up more than 43% of that market value! Designing and manufacturing AAV vectors is complex, and to be successful, certain challenges must be addressed. This implies monitoring and optimtizing production for a thorough quality control process, including reliable ongoing characterization of process intermediates and the final product. Key features include: Overview and data on the gene therapy market Description of AAV vectors’ genomes and transfer Challenges associated with AAV vectors’ design and manufacturing Analytical methods for AAV vector quality control with a description of innovative no-wash AlphaLISA™ assays

Flyer
Flyer
Advance your biologics research with Revvity solutions

In the dynamic landscape of pharmaceuticals, biotherapeutics research stands out as the fastest-growing sector. Scientists worldwide are on a quest for ever more efficient tools to develop therapeutic proteins. From lead selection to bioprocessing qualification, rigorous analytical characterization is essential. That’s where Revvity steps in. Our comprehensive line of no-wash tools revolutionizes biologics screening, mechanism-of-action studies, and biomanufacturing. With robustness and convenience at the forefront, we empower researchers to accelerate discoveries and drive innovation. Welcome to a new era of precision and efficiency in biotherapeutics research. For research use only. Not for use in diagnostic procedures.

Application Note
Application Note
Advancing K-Ras Targeted Therapies with Innovative Detection Methods

The RAS family of genes, particularly K-Ras, plays a critical role in cancer biology. Despite its notorious difficulty as a therapeutic target, recent breakthroughs have brought new hope in treating cancers driven by K-Ras mutations. Our latest application note delves into innovative approaches to K-Ras inhibition, including small molecule inhibitors, synthetic lethality strategies, and PROTAC® molecules. We also showcase the high specificity and sensitivity of the no-wash HTRF™ K- Ras immunoassay, a cutting-edge tool that offers a reliable and precise method for evaluating K-Ras protein levels, outperforming traditional techniques. Discover how this assay can accelerate your research in targeting the elusive K-Ras.

Application Note
Application Note
Advantages of using our automatable and no-wash HTRF and AlphaLISA kits for CHO HCP detection

Detecting and quantifying HCPs with automatable homogeneous immunoassays During biotherapeutic manufacturing and production, the host cells - a great majority of them being Chinese Hamster Ovary (CHO) cells – produce protein impurities that are called Host Cell Proteins (HCPs). Even if more than 99% of them are removed from the final product, the residual CHO HCPs can induce immunogenicity in individuals or reduce the potency, stability, or effectiveness of a drug. Therefore, to meet regulatory organizations’ guidelines (such as FDA or EMA) on CHO HCP levels, biopharmaceutical companies spend significant amounts of money on tools and strategies for their detection. Illustrated with robust results, this Application Note explains the many ways in which HTRF™ and AlphaLISA™ kits can improve the workflow for CHO HCP detection: Wide antibody coverage Compatibility with most commonly used buffers No cross-reactivity between CHO HCP detection and drug substance Good dilutional linearity and antigen spike recovery

Brochure
Brochure
Alpha SureFire Ultra no-wash immunoassay catalog

Discover Alpha SureFire ®   Ultra ™ assays, the no-wash cellular kinase assays leveraging Revvity's exclusive bead-based technology and sandwich immunoassays for detecting phosphorylated proteins in cells. Offering a quantitative alternative to Western Blotting, Alpha SureFire assays are automation-friendly, easily miniaturized, and proficient in detecting both endogenous and recombinant proteins. Explore our comprehensive portfolio of SureFire Assays, designed to help you elevate and expedite your drug discovery journey.

Guide
Guide
AlphaLISA SureFire Ultra assay optimization

This guide outlines further possible optimization of cellular and immunoassay parameters to ensure the best possible results are obtained.

Guide
Guide
AlphaLISA SureFire Ultra: the ultimate guide for successful experiments

The definitive guide for setting up a successful AlphaLISA SureFire Ultra assay Several biological processes are regulated by protein phosphorylation. It is, therefore, no surprise that the dysregulation of protein phosphorylation is implicated in a relatively large number of diseases. AlphaLISA SureFire Ultra assays provide a robust and reliable method for quantifying a targeted phosphorylation event in cell-based experiments. This guide contains tools and data helpful for you to perform your assays using AlphaLISA SureFire Ultra: A detailed description of the assay and its options A thorough investigation of assay conditions to obtain the optimal response from the chosen modulator and cell line A list of optimization steps to provide a sufficient assay window and produce the strongest results possible

Guide
Guide
AlphaPlex quick start guide

The AlphaPlex™ reagent system was designed to enable fast and easy transition from well-established AlphaLISA™ assays to multiplexed detection of a broad range of proteins, molecules and biomarkers. Using a universal, streptavidin-coated Donor bead, multiple AlphaPlex Acceptor beads targeted to various analytes are combined in a single assay well. Download this guide to learn how to easily set up your AlphaPlex assay and streamline your workflow! For research use only. Not for use in diagnostic procedures.

Whitepaper
Whitepaper
An overview of atherosclerosis

Atherosclerosis pathogenesis, cellular actors, and pathways Atherosclerosis is a common condition in which arteries harden and become narrow due to a build-up of fatty material, usually cholesterol, and other substances such as calcium. This can lead to a range of serious health complications, including heart attack or stroke, making the disease an important contributing factor in death and morbidity in developed countries. Recent developments in our understanding of atherosclerosis from a molecular perspective include the discovery of new players in disease pathogenesis. Included in this white paper Atherosclerosis: step-by-step pathogenesis, therapeutic strategies, and recent developments Detailed descriptions and explanations, including a focus on pathways

Whitepaper
Whitepaper
Antibody-based therapeutic modalities in oncology

With over 200 different types of cancer, management relies on a variety of techniques such as chemotherapy, radiotherapy, and surgery. These types of therapies can be associated with severe side effects, and finding safer and more effective treatments is a priority in cancer therapeutics research. One approach that has shown huge potential is monoclonal antibody-based cancer therapeutics. In this white paper we explore this exciting area of anti-cancer research, covering mechanism of action, development, and challenges in monoclonal antibody-based therapeutics, including antibody-drug conjugates and multispecific antibodies.

Application Note
Application Note
Assessment of drug efficacy and toxicity by combining innovative technologies

Compound MoA and potential cytotoxic effects deciphered thanks to immunoassays and cell viability assay The attrition of drug molecules occurs at various stages in the development process, and most early-phase failures are attributed to safety and toxicity issues. Considering the economic impact of early project termination, the biggest challenge comes from selecting the most potent and selective drug compounds while assessing their potential toxic side effects. In this application note, you’ll discover how to easily combine AlphaLISA™, HTRF™, or AlphaLISA™ SureFire® Ultra™ immunoassays with the ATPlite™ 1step cell viability assay to simultaneously, and in a single sample, study the efficacy of drug compounds on disease pathways while identifying possible cytotoxic effects. Recommendations Detailed workflows Case studies on various cell lines and different markers using HTRF, AlphaLISA, or AlphaLISA SureFire Ultra immunoassays together with the ATPlite 1step cell viability assay

eBook
eBook
Autophagy regulation eBook

Taking autophagy regulation research a step further Autophagy regulation is a key molecular process involved in recycling long-lived protein and organelles. Dysregulation of autophagy leads to different pathologies such as cancer, neurodegenerative and infectious diseases. This eBook features: Key facts about autophagy and mitophagy Infographics to apprehend the basics Cutting-edge knowledge

Guide
Guide
Benefit from a collection of important NAFLD pathways

Get a useful overview of today’s NAFLD knowledge with this booklet. NASH disease is complex and follows many development pathways. This booklet provides you with critical information regarding NAFLD and more specifically about NASH progression. Review the fundamentals of NAFLD and NASH learn from an important research report Benefit from additional content to help your NASH research

Guide
Guide
Benefit from an insight into the diversity of immune cells & signaling pathways

Get a useful overview of today’s immunity knowledge with this booklet Immunity is a collection of complex processes involving multiple strategies and specialized cell types. This booklet provides you with critical information regarding their roles, characteristic and signaling pathways as well as the collaborative behaviors that contribute to immunity. Featured in this guide: Review the fundamentals of immune cell types and mechanisms Learn from a cutting-edge research report Pathways and functional details on over 10 specialized immune cells

Application Note
Application Note
cAMP AlphaScreen assay: a method for the pharmacological characterization and screening of Gαi coupled receptors in whole cells

G protein-coupled receptors (GPCRs) are a large family of transmembrane receptors that are significant drug targets. They function as enzymes that activate G-proteins. GPCRs couple to three main families of Gα subunits: Gαi/o, Gαs, and Gαq. The coupling specificity depends on the GPCR and its cellular environment. Gαs and Gαi subunits operate through the cAMP pathway, either activating or inhibiting adenylate cyclase, which converts ATP to cAMP. In this application note, the AlphaScreen™-based cAMP detection technology has been used to study Gαi-coupled receptors, specifically the 5-hydroxytryptamine-1A (5-HT1A) serotonergic receptor. The note demonstrates the utility of the AlphaScreen-based cAMP Assay kit for the pharmacological characterization and potential high-throughput screening of Gαi-coupled receptors.

Application Note
Application Note
cAMP assay provides flexibility and stable pharmacology

G protein-coupled receptors (GPCRs) play a crucial role in various cellular and physiological processes, including cell proliferation, differentiation, neurotransmission, development, and apoptosis. GPCR activity is commonly assessed by measuring levels of intracellular cAMP upon stimulation by agonists. Abnormal GPCR activity is associated with many diseases, including cancer, making GPCRs an important class of pharmaceutical drug targets. Multiple assay formats have been developed to measure the level of cAMP generated, which can determine the pharmacological potency of different agonists and antagonists. The ideal assay is homogeneous, non-radioactive, and allows for sensitive and reproducible detection. AlphaScreen ™ technology provides a quantitative detection of molecules in a homogeneous, no-wash format and can be applied to GPCR research. Download this application note to learn more on the cAMP AlphaScreen assay: Detailed protocol, Data illustrated by graph and tables, Dynamic range description and validation.

Application Note
Application Note
CDK signaling in oncology: assess the effectiveness of a CDK9-targeting PROTAC molecule

CDK9 is an attractive target for cancer therapeutics due to its crucial role in transcription regulation, particularly of short-lived anti-apoptotic proteins such as MCL-1 and XIAP which are critical to the survival of cancer cells. One approach for specifically degrading CDK9 is using a proteolysis targeting chimera (PROTAC). In this application note, you will discover: The rapid and strong effect of CDK9 PROTAC molecule Thal-SNS-032, demonstrating specificity in CDK9 degradation How HTRF ® and AlphaLISA ® SureFire ® Ultra ™ are used to measure protein levels, with each tool showcasing the ability of PROTACs to rapidly degrade a targeted protein making it a unique tool in the fight against cancer

Application Note
Application Note
CDK signaling: Investigate CDK4/6 inhibition in breast cancer cell lines with HTRF immunoassays

Cyclin-dependent kinases (CDKs) 4 & 6 play a key in breast cancer. Cyclin D1-CDK4/6 complexes are critical regulators of the cell cycle transition from the G1 to S phase. To proceed through these phases, a cell must pass a restrictive checkpoint, tightly regulated in this case by the retinoblastoma tumor suppressor protein (Rb). Palbociclib is a small molecule kinase inhibitor that blocks Cyclin D1-CDK4/6 mediated phosphorylation of the Rb protein to prevent E2F driven transcription of genes that commit the cell to DNA replication and cell division. In this application note, you will learn: The effect of palbociclib treatment in two breast cancer cell lines How to monitor the amount of phospho-Rb and Cyclin D1 protein levels with HTRF® ® immunoassays to examine the effect of CDK4/6 inhibition and Cyclin D1 regulation

Whitepaper
Whitepaper
Cell-based assays: Purposeful screens for better results

Over these last few decades there has been a growing trend in drug discovery to use cellular systems and functional assays, in addition to biochemical assays, for the characterization of new potential therapeutics. The ability to study the interaction between a candidate drug and its target within the context of a whole, intact cell allows for more physiologically relevant data to be obtained. However, such assays are more complex than traditional biochemical assays as such facts as membrane permeability, cellular metabolism, cell variability, additional binding partners, and signal transduction must be considered. To help you navigate the complexities in designing cell-based assays, we have gathered insights collected over the years and compiled them to provide you with elements to consider when setting up your cell-based assays. After all, any assay, biochemical or cell-based, is only as good as its design.

Application Note
Application Note
Characterization of candidate molecules through GTP binding assays

Enhance your GTP measurements with this application note δ-opioid receptors (DOP) have become a major target for the development of new pain treatments. This application note will show you how to characterize pharmacological compounds easily through GTP binding assays: Measuring the level of Gi protein activation Using a CHO membrane model expressing delta opioid receptor Several case studies for the different classes of pharmacological compounds

Application Note
Application Note
Characterizing chemokine receptor inhibitors with AlphaLISA SureFire Ultra, Alpha SureFire Ultra Multiplex and LANCE Ultra cAMP assays

The measurement of protein phosphorylation is a useful tool for measuring the modulation of receptor activation by both antibodies and small molecules. CCR7 and CXCR2 receptors, which are expressed in immune cells and are therapeutic targets for disorders like lupus erythematosus, adult leukemia, lymphomas, chronic obstructive pulmonary disease (COPD), and sepsis. AlphaLISA ™ SureFire ® Ultra ™ and Alpha SureFire ® Ultra ™ Multiplex assays are automation-friendly, applicable to both small and large-scale screens, and can assess phosphorylation status in complex matrices. The LANCE Ultra cAMP assay is measures cyclic AMP (cAMP) produced upon modulation of adenylyl cyclase activity by G-protein coupled receptors (GPCRs). This application note demonstrates how the SureFire Ultra and LANCE Ultra cAMP assays can be used for measuring inhibitors to CCR7 and CXCR2 cell surface receptors using a cellular model system where these receptors are overexpressed in CHO cells. The assays were optimized to measure receptor blockage and assayed receptor activity modulation by detecting ERK and AKT phosphorylation status and cAMP modulation. For more details, download the application note!

Application Note
Application Note
Characterizing compounds acting on β-arrestin2 coupled GPCRs

Dive deeper into research on the GPCR signaling pathway β-arrestins are intracellular proteins that play an important role in GPCR signaling. Complexes formed between ligand-occupied GPCRs and β-arrestin lead to interaction with adaptor protein AP2. This interaction is followed by internalization of the receptors. HTRF technology is effective for studying the interaction between AP2 and β-arrestin2. Get your application note to discover: The applicability of the β-arr2 recruitment kit to a variety of compounds acting on β-arrestin2, and its ability to correctly rank pharmacological compounds (agonists and antagonists) How you can detect the β-arrestin2 / AP2 interaction for all classes of GPCRs Detailed experimental conditions and explanatory diagrams

References

  1. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  2. Jones B,et al. In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist. Diabetes Obes Metab. 2022 Nov;24(11):2090-2101. doi: 10.1111/dom.14794. Epub 2022 Jul 18. PMID: 35676825; PMCID: PMC9796023.
  3. Lucey M, et al. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists. Mol Metab. 2020 Jul;37:100991. doi: 10.1016/j.molmet.2020.100991. Epub 2020 Apr 8. PMID: 32278079; PMCID: PMC7262448.
  4. Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, Volume 34, Issue 9, 1234 - 1247.e9. c. doi: j.cmet.2022.07.013
  5. McGlone E.R et al. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity. Biomedicine & Pharmacotherapy, Volume 176, 2024. https://doi.org/10.1016/j.biopha.2024.116888
  6. Fontaine, T., Busch, A., Laeremans, T. et al. Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonist. Nat Commun 15, 7029 (2024). https://doi.org/10.1038/s41467-024-50827-7
  7. Chichura, K.S., Elfers, C.T., Salameh, T.S. et al. A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss. Sci Rep 13, 9554 (2023). https://doi.org/10.1038/s41598-023-36178-1
  8. Roed SN, et al. Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Mol Cell Endocrinol. 2014 Feb 15;382(2):938-49. doi: 10.1016/j.mce.2013.11.010. Epub 2013 Nov 22. PMID: 24275181.